Bio
Tinghu Zhang is a senior research scientist at Cancer Institute of Stanford. Dr. Zhang is an expert in chemical biology and medicinal chemistry. His research focuses on using the small molecule inhibitor and degrader to investigate the biology and pharmacology of protein targets which include kinases and transcription factors. Tinghu made significant contributions to the field of chemical biology by discovering several first-in-class covalent inhibitors for variety of protein targets such as JNK, CDK7, CDK12/13, TEAD and PIP4K. Tinghu is also a pioneer scientist in the development of degrader molecular and most recently bivalent TCIP (Transcription Chemical Inducer Proximity). Tinghu also led several translational programs with industrial sponsors. Under his leadership, several prototype molecules have been out-licensed to the established pharmaceutical companies or biotech startups. Prio to Stanford, Tinghu was a senior scientist and the chemistry group leader at the Center of Protein Degradation (CPD) at Dana-Farber Cancer Institute. Dr. Zhang received his PhD in chemistry from USTC (China) in 2004.
